Business Context and Reporting Period
Company: ANAPTYSBIO, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: November 24, 2023
Event: Entry into a Material Definitive Agreement with Centessa Pharmaceuticals (UK) Limited.
Key Financial Metrics and Transaction Details
This filing reports a specific licensing transaction rather than periodic financial performance. Key financial terms include:
- Upfront Cash Payment: $4 million.
- Supply Payment: $3 million for manufactured and released GMP supply of the asset CBS004 (renamed ANB101).
- Total Initial Payment: $7 million.
- Future Milestone: Up to $10 million payable upon initiation of the first Phase 3 clinical trial (payable in cash or common stock).
- Royalties: Low single-digit royalties on global net sales.
Note: The filing does not provide data on overall revenue, profit, cash flow, margins, debt, or liquidity for the company.
Material Changes and Asset Acquisition
AnaptysBio secured an exclusive worldwide license for Centessa's blood dendritic cell antigen 2 (BDCA2) modulator antibody portfolio. This includes the lead asset CBS004 (now ANB101) and related backup antibodies intended for the treatment of autoimmune and inflammatory diseases. The agreement was announced via press release on November 27, 2023.
Outlook, Risks, and Contractual Terms
- Termination Rights: AnaptysBio may terminate the agreement with 90 days' written notice. Either party may terminate in the event of a breach (subject to cure) or bankruptcy.
- Reversion Rights: The agreement includes customary reversion rights upon termination.
- Regulatory Status: The press release and related information are not deemed "filed" for purposes of Section 18 of the Exchange Act and are not incorporated by reference except as expressly stated.
Investor Verification Checklist
- Verify the impact of the $7 million cash outflow on the company's current cash reserves and runway.
- Review the full text of the License Agreement (to be filed as an exhibit to the 2023 Form 10-K) for detailed definitions of "global net sales" and royalty tiers.
- Assess the clinical development timeline for ANB101 to estimate the timing of the potential $10 million milestone payment.
- Confirm the status of the GMP supply delivery for the $3 million payment component.